Physician profile
Dmitry Youshko
NPI 1508158015
$4,685.65
in general payments reported to CMS, 2019-2025
24 companies · $996 in 2025
The $996 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $816 · 2020: $291 · 2021: $303 · 2022: $458 · 2023: $1,075 · 2024: $746 · 2025: $996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,799 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,798.52 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,240.96 | 2019-2023 | Lo Loestrin Fe |
| Astellas Pharma US INC | $861.66 | 2021-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $326.90 | 2023-2025 | Slynd |
| Mayne Pharma Commercial LLC | $276.05 | 2023-2025 | |
| Femselect INC. | $237.81 | 2025 | Enplace |
| Baxter Healthcare | $228.51 | 2021-2023 | Tisseel |
| Evofem Biosciences, INC. | $199.88 | 2023-2025 | Phexxi, Solosec, Phexx |
| Davol INC. | $154.50 | 2023 | |
| Biogen, INC. | $126.47 | 2024-2025 | Zurzuvae |
| Glaxosmithkline, LLC. | $124.99 | 2023 | Arexvy |
| Shield Therapeutics INC | $124.12 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $122.88 | 2023-2025 | Myfembree |
| Ethicon US, LLC | $117.04 | 2021 | |
| Applied Medical Resources Corporation | $116.62 | 2022 | |
| Hologic Sales and Service, LLC | $107.37 | 2022-2025 | Aptima, Thinprep 2000 Processor |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $74.58 | 2022-2023 | Paragard T 380a |
| Organon LLC | $66.95 | 2023-2025 | Nexplanon |
| Lupin INC. | $42.56 | 2019-2020 | |
| Myovant Sciences INC. | $30.83 | 2021-2022 | |
| Therapeuticsmd, INC. | $24.83 | 2022 | |
| Millicent US INC | $23.20 | 2025 | Femlyv |
| Pfizer INC. | $21.20 | 2024 | |
| Aspira Women'S Health INC | $18.31 | 2022 | |
| Olympus America INC. | $17.43 | 2025 | Olympus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitry Youshko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.